Shockwave Confirms Consistent Outcomes for IVL in the Largest Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

Disrupt PAD III Observational Study Results Confirm Safety and Effectiveness of IVL in Patients with Complex Calcified Lesions

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the final 1,373-patient cohort analysis from the Disrupt PAD III Observational Study (OS) again demonstrates consistent IVL outcomes in complex and challenging lesions across multiple peripheral vessel beds.

The study represents the largest prospective “real world” evidence supporting the treatment of complex, heavily calcified peripheral artery disease (PAD) with IVL. The final analysis was presented earlier today at VIVA22 in a late-breaking clinical trial session.

The key findings from Disrupt PAD III OS include:

  • IVL resulted in consistent reduction in the diameter of stenosis with no associated distal embolization, abrupt closure or thrombotic events at any time
  • IVL was the only calcium-modifying therapy used in most cases, required a limited need for adjunctive therapy tools (i.e., embolic protection), and had better results with appropriate IVL sizing
  • IVL results were comparable to the previously reported outcomes from the Disrupt PAD III randomized clinical trial (RCT) showing that IVL safely and effectively modifies calcium across multiple peripheral vessel beds

“These consistent results in a ‘real world’ population, combined with the recent long-term outcomes from the Disrupt PAD III RCT, reinforce the positioning of IVL as a reliable, potential first-line therapy for the treatment of large and diverse patient populations with calcified peripheral arterial disease,” said Ehrin J. Armstrong, MD, Medical Director, Adventist Heart and Vascular Institute, St. Helena, CA. “The significant amount of data on IVL continue to show both consistent efficacy and safety across the most challenging lesions, various peripheral vessel beds, and even in the most complex, high-risk patients.”

Disrupt PAD III OS is a prospective, multicenter, single-blind study of “real world” patients. The analysis looked at the total 1,373-patient cohort enrolled in the study from November 2017 to June 2021 at 30 global sites. Of the 1,531 lesions treated in the iliac, common femoral, superficial femoral, popliteal and infra-popliteal arteries, 90 percent presented with moderate/severe calcification, with an average calcified length of 115 millimeters. The use of IVL in these lesions resulted in a final residual diameter stenosis of 24 percent, similar to Disrupt PAD III RCT (22 percent). Patients also experienced minimal procedural complications, with only 0.7 percent and 0.2 percent experiencing final dissections (Type D-F) and perforations, respectively. Notably, there were no instances of embolization, thrombus formation, no reflow or abrupt closure.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy